Total Serum Transforming Growth Factor‐β1 Is Elevated in the Entire Spectrum of Genetic Aortic Syndromes

Total serum transforming growth factor‐beta 1 (tsTGF‐β1) is increased in patients with Marfan syndrome (MFS), but it has not been assessed in thoracic aortic aneurysm and dissection (TAAD), Loeys‐Dietz syndrome (LDS), and bicuspid aortic valve disease (BAVD).

[1]  S. Blankenberg,et al.  Dural ectasia in Loeys–Dietz syndrome: comprehensive study of 30 patients with a TGFBR1 or TGFBR2 mutation , 2014, Clinical genetics.

[2]  S. Blankenberg,et al.  Comprehensive analysis of dural ectasia in 150 patients with a causative FBN1 mutation , 2014, Clinical genetics.

[3]  G. Rosenberger,et al.  A 1-bp duplication in TGFB2 in three family members with a syndromic form of thoracic aortic aneurysm , 2013, European Journal of Human Genetics.

[4]  H. Dietz,et al.  Loeys–Dietz syndrome: a primer for diagnosis and management , 2014, Genetics in Medicine.

[5]  R. Pyeritz.  Heritable thoracic aortic disorders , 2014, Current opinion in cardiology.

[6]  A. Zwinderman,et al.  Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndrome. , 2013, International journal of cardiology.

[7]  B. Loeys,et al.  Genetics of thoracic aortic aneurysm: at the crossroad of transforming growth factor-β signaling and vascular smooth muscle cell contractility. , 2013, Circulation research.

[8]  J. Elefteriades,et al.  Biomarkers in TAA-the Holy Grail. , 2013, Progress in cardiovascular diseases.

[9]  Paul Coucke,et al.  Novel MYH11 and ACTA2 mutations reveal a role for enhanced TGFβ signaling in FTAAD. , 2013, International journal of cardiology.

[10]  S. Takamoto,et al.  Circulating transforming growth factor β-1 level in Japanese patients with Marfan syndrome. , 2013, International heart journal.

[11]  Y. Suh,et al.  Positive correlation between the dysregulation of transforming growth factor-β1 and aneurysmal pathological changes in patients with Marfan syndrome. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[12]  J. Coselli,et al.  Notch Signaling in Descending Thoracic Aortic Aneurysm and Dissection , 2012, PloS one.

[13]  E. Boerwinkle,et al.  Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons ≥15 years of age. , 2012, The American journal of cardiology.

[14]  H. Dietz,et al.  Matrix‐dependent perturbation of TGFβ signaling and disease , 2012, FEBS letters.

[15]  R. Pyeritz.  Evaluation of the adolescent or adult with some features of Marfan syndrome , 2012, Genetics in Medicine.

[16]  D. Sillence,et al.  Mutations in the TGFβ binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias. , 2011, American journal of human genetics.

[17]  Laurence Faivre,et al.  The revised Ghent nosology for the Marfan syndrome , 2010, Journal of Medical Genetics.

[18]  Stephan Willems,et al.  Augmentation index relates to progression of aortic disease in adults with Marfan syndrome. , 2009, American journal of hypertension.

[19]  H. Dietz,et al.  Circulating Transforming Growth Factor-&bgr; in Marfan Syndrome , 2009, Circulation.

[20]  A. Al Haj Zen,et al.  Syndromic and non‐syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway , 2009, The Journal of pathology.

[21]  P. Robinson,et al.  The spectrum of syndromes and manifestations in individuals screened for suspected Marfan syndrome , 2008, American journal of medical genetics. Part A.

[22]  A. Dart,et al.  Angiotensin II blockade in Marfan's syndrome. , 2008, The New England journal of medicine.

[23]  J. Rosenbloom,et al.  Angiotensin II blockade in Marfan's syndrome. , 2008, The New England journal of medicine.

[24]  A. Dart,et al.  Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. , 2007, JAMA.

[25]  M Claustres,et al.  Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. , 2007, American journal of human genetics.

[26]  P. Byers,et al.  Aneurysm syndromes caused by mutations in the TGF-beta receptor. , 2006, The New England journal of medicine.

[27]  George H. Thomas,et al.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2006 .

[28]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[29]  William Stewart,et al.  Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[30]  Wolfram Kress,et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.

[31]  R E Pyeritz,et al.  Revised diagnostic criteria for the Marfan syndrome. , 1996, American journal of medical genetics.

[32]  E. F. Du Bois,et al.  A formula to estimate the approximate surface area if height and weight be known. 1916. , 1989, Nutrition.

[33]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .